Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780806 | 0.95 | NPC1L1 (0.43) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL6483529 | 0.94 | OPRM1 (0.48) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5780332 | 0.91 | OPRM1 (0.47) | NPC1L1ENPP2OPRM1OPRL1OPRD1 | |
| SCHEMBL5785798 | 0.91 | NPC1L1 (0.45) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5783193 | 0.90 | L3MBTL1 (0.44) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5781729 | 0.90 | OPRM1 (0.50) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5782239 | 0.90 | ENPP2 (0.43) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5779165 | 0.90 | NPC1L1 (0.51) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5780117 | 0.90 | NPC1L1 (0.44) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 | |
| SCHEMBL5780452 | 0.88 | ENPP2 (0.51) | NPC1L1ENPP2BDKRB2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1329451-B1 | SPIRO COMPOUNDS AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-6919349-B2 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES, INC. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES INC. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1329451-A1 | SPIRO COMPOUNDS AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | VCAM1, ICAM1, SELL | NPC1L1 2533/4885ENPP2 1140/4885BDKRB2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.